| Bevacizumab plus irinotecan in recurrent glioblastoma multiforme JJ Vredenburgh, A Desjardins, JE Herndon, J Marcello, DA Reardon, ... Journal of clinical oncology 25 (30), 4722-4729, 2007 | 1511 | 2007 |
| Phase II trial of gefitinib in recurrent glioblastoma JN Rich, DA Reardon, T Peery, JM Dowell, JA Quinn, KL Penne, ... Journal of Clinical Oncology 22 (1), 133-142, 2004 | 787 | 2004 |
| Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma JH Sampson, AB Heimberger, GE Archer, KD Aldape, AH Friedman, ... Journal of clinical oncology 28 (31), 4722, 2010 | 697 | 2010 |
| Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma JH Sampson, JH Carter, AH Friedman, HF Seigler Journal of neurosurgery 88 (1), 11-20, 1998 | 562 | 1998 |
| Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma PE Fecci, DA Mitchell, JF Whitesides, W Xie, AH Friedman, GE Archer, ... Cancer research 66 (6), 3294-3302, 2006 | 480 | 2006 |
| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The Lancet Oncology 18 (10), 1373-1385, 2017 | 384 | 2017 |
| Proteomic and immunologic analyses of brain tumor exosomes MW Graner, O Alzate, AM Dechkovskaia, JD Keene, JH Sampson, ... The FASEB Journal 23 (5), 1541-1557, 2009 | 380 | 2009 |
| Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma S Kunwar, S Chang, M Westphal, M Vogelbaum, J Sampson, G Barnett, ... Neuro-oncology 12 (8), 871-881, 2010 | 366 | 2010 |
| Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma DA Mitchell, W Xie, R Schmittling, C Learn, A Friedman, RE McLendon, ... Neuro-oncology 10 (1), 10-18, 2008 | 365 | 2008 |
| Immunotherapy response assessment in neuro-oncology: a report of the RANO working group H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ... The Lancet Oncology 16 (15), e534-e542, 2015 | 351 | 2015 |
| Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients DA Mitchell, KA Batich, MD Gunn, MN Huang, L Sanchez-Perez, SK Nair, ... Nature 519 (7543), 366-369, 2015 | 351 | 2015 |
| Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme DA Reardon, MJ Egorin, JA Quinn, JN Rich, I Gururangan, ... Journal of Clinical Oncology 23 (36), 9359-9368, 2005 | 345 | 2005 |
| Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion A Lal, CA Glazer, HM Martinson, HS Friedman, GE Archer, JH Sampson, ... Cancer research 62 (12), 3335-3339, 2002 | 319 | 2002 |
| Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group S Kunwar, MD Prados, SM Chang, MS Berger, FF Lang, JM Piepmeier, ... Journal of Clinical Oncology 25 (7), 837-844, 2007 | 302 | 2007 |
| Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly … DA Reardon, G Akabani, R Edward Coleman, AH Friedman, HS Friedman, ... Journal of Clinical Oncology 20 (5), 1389-1397, 2002 | 293 | 2002 |
| Phase II trial of temozolomide in patients with progressive low-grade glioma JA Quinn, DA Reardon, AH Friedman, JN Rich, JH Sampson, ... Journal of clinical oncology 21 (4), 646-651, 2003 | 287 | 2003 |
| Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma JH Sampson, KD Aldape, GE Archer, A Coan, A Desjardins, AH Friedman, ... Neuro-oncology 13 (3), 324-333, 2011 | 273 | 2011 |
| Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the … JH Sampson, G Akabani, GE Archer, DD Bigner, MS Berger, AH Friedman, ... Journal of neuro-oncology 65 (1), 27-35, 2003 | 269 | 2003 |
| An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme JH Sampson, GE Archer, DA Mitchell, AB Heimberger, JE Herndon, ... Molecular cancer therapeutics 8 (10), 2773-2779, 2009 | 267 | 2009 |
| Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma JA Quinn, SX Jiang, DA Reardon, A Desjardins, JJ Vredenburgh, JN Rich, ... Journal of Clinical Oncology 27 (8), 1262, 2009 | 263 | 2009 |
Patrick C. Gedeon, M.D., Ph.D.Brigham and Women's HospitalVerified email at partners.org
